TICAR INJ PWS 1GM/VIAL DIN 01916920
Status: Cancelled Post Market
Holder: SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC
Molecule: TICARCILLIN DISODIUM
Health Canada record
| Active ingredient(s) | TICARCILLIN DISODIUM 1 G |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous; Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01CA13 TICARCILLIN |
| Original market date | 31-Dec-1992 |
| Current status date | 12-Sep-1996 |
| Source | Health Canada DPD |
Establishment licence of the holder
Smithkline Beecham Ltd T/A Smithkline Beecham Pharmaceuticals — licence , not currently licensed, last inspection rating C (2024-12-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TICARCILLIN DISODIUM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 01916912 | TICAR INJ PWS 3GM/VIAL | SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC | Powder For Solution | TICARCILLIN DISODIUM 3 G | Cancelled Post Market |
International API supply for TICARCILLIN DISODIUM
0 active FDA Drug Master Files.
Request a quote for TICAR INJ PWS 1GM/VIAL